The General Hospital Corporation Research Management Division, doing business as Massachusetts General Hospital (MGH), was awarded a $1,127,798 Project Grant under the National Heart, Lung, and Blood Institute's (NHLBI) Cardiovascular Diseases Research program (CFDA 93.837). The award, effective February 1, 2025 through January 31, 2032, supports research to understand the role of macrophages in preserving cardiovascular health, illuminating their contributions to cardiovascular disease (CVD), and defining new therapeutic targets for CVD patients. The research aims to advance understanding of innate immunity in CVD, identify harmful macrophage subsets and functions, and explore regulatory pathways that could serve as immunomodulatory targets. The ultimate goal is to develop a macrophage drug target for CVD.
Generated 3/4/25, 4:57 AM